Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome

Overview

Journal Case Rep Nephrol Dial

Specialty Nephrology

Date 2017 Jun 15

PMID 28612006

Authors

Thomas R Welch

David R Shaffer

Darren R Feldman

Affiliations

Soon will be listed here.

Abstract

A 30-year-old man with severe antenatal Bartter syndrome, diagnosed and treated in infancy, developed testicular carcinoma. Despite the known renal complications of cisplatin, this drug was used for his chemotherapy because of its superior antineoplastic effect. Nonsteroidal anti-inflammatory drug administration was continued during cisplatin therapy. Despite an increase in his oral potassium requirement, renal function was maintained following completion of chemotherapy. In spite of its significant associated nephrotoxicity, cisplatin can be used in patients with severe antenatal Bartter syndrome if required for therapy of malignancy.

References

Simon D, Karet F, Rodriguez-Soriano J, Hamdan J, Dipietro A, Trachtman H . Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996; 14(2):152-6. DOI: 10.1038/ng1096-152. View

Bartter F, PRONOVE P, GILL Jr J, MacCARDLE R . Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med. 1962; 33:811-28. DOI: 10.1016/0002-9343(62)90214-0. View

Reinalter S, Grone H, Konrad M, Seyberth H, Klaus G . Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr. 2001; 139(3):398-406. DOI: 10.1067/mpd.2001.117007. View

Restrepo de Rovetto C, Welch T, Hug G, Clark K, Bergstrom W . Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism. J Pediatr. 1989; 115(3):397-404. DOI: 10.1016/s0022-3476(89)80838-8. View

Miller R, Tadagavadi R, Ramesh G, Reeves W . Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2011; 2(11):2490-518. PMC: 3153174. DOI: 10.3390/toxins2112490. View

Seyberth H, Rascher W, Schweer H, Kuhl P, Mehls O, Scharer K . Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr. 1985; 107(5):694-701. DOI: 10.1016/s0022-3476(85)80395-4. View

Kockerling A, Reinalter S, Seyberth H . Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. J Pediatr. 1996; 129(4):519-28. DOI: 10.1016/s0022-3476(96)70116-6. View

Ramesh G, Reeves W . TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002; 110(6):835-42. PMC: 151130. DOI: 10.1172/JCI15606. View

Shoemaker L, Welch T, Bergstrom W, Abrams S, Yergey A, Vieira N . Calcium kinetics in the hyperprostaglandin E syndrome. Pediatr Res. 1993; 33(1):92-6. DOI: 10.1203/00006450-199301000-00019. View

10.

Simon D, Karet F, Hamdan J, Dipietro A, Sanjad S, Lifton R . Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996; 13(2):183-8. DOI: 10.1038/ng0696-183. View

11.

Bajorin D, Sarosdy M, Pfister D, Mazumdar M, Motzer R, Scher H . Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993; 11(4):598-606. DOI: 10.1200/JCO.1993.11.4.598. View

12.

Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F . Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion. Nature. 2001; 414(6863):558-61. DOI: 10.1038/35107099. View

13.

Horwich A, Sleijfer D, Fossa S, Kaye S, Oliver R, Cullen M . Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for.... J Clin Oncol. 1997; 15(5):1844-52. DOI: 10.1200/JCO.1997.15.5.1844. View